Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EDP167

Phase 2Small molecule

EEddingpharm (Zhuhai) Co., Ltd.

2

Indications

3

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Homozygous Familial Hypercholesterolemia (hofh)Recruiting

Mixed DyslipidemiaNot yet recruiting

Homozygous Familial Hypercholesterolemia (hofh)Phase 2

Recruiting

Mixed DyslipidemiaPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Study completion

NCT07489209

Q2 2028

Phase 2Not yet recruiting

Mixed Dyslipidemia

NCT07799129

Clinical

Trials by Indication[1]

Dyslipidemia1 trial

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

Completed·EEddingpharm (Zhuhai) Co., Ltd.·Phase 1·NCT07412080·40 enrolled

Mixed Dyslipidemia1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Study to Evaluate the Efficacy and Safety of EDP167 in Adult Patients With Mixed Dyslipidemia

Not yet recruiting·EEddingpharm (Zhuhai) Co., Ltd.·Phase 2·NCT07799129·144 enrolled

Unspecified1 trial

A Dose-exploration Study of EDP167 in HoFH

Recruiting·EEddingpharm (Zhuhai) Co., Ltd.·Phase 2·NCT07489209·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for EDP167. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EDP167 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EDP167. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eddingpharm (Zhuhai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEddingpharm (Zhuhai) Co., Ltd.

Related News